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MODULATION OF 
ALLOREACTIVITY IN 
TRANSPLANT RECIPIENTS 
BY PHENOTYPIC 
MANIPULATION OF DONOR 
ENDOTHELIUM 
Phenotypic manipulation of allograft endothelium to reduce immunogenicity would 
have a significant impact on transplantation. In this study we have demonstrated 
that random seeding of a heart allograft with endothelium, of host origin, not only 
promotes long-term survival, but reduces the requirement for pharmacologic 
immunosuppression. We propose that this simple technology could easily be 
extrapolated to the clinical arena where hypothermia and preservation solutions 
have allowed allografts to remain ex vivo for extended periods. (J THORAC 
CARDIOVASC SURG 1995;109:905-9) 
R. L. Quigley, MD, DPhil, a S. S. Switzer, BS, a T. A. Victor, MD, b 
R. A. Goldschmidt, MD, b M. H. Salinger, MD, c C. E. Arentzen, MD, a 
J. C. Alexander, MD, a and R. W. Anderson, MD, a Evanston, Ill. 
D isparity in the major histocompatibility complex 
(MHC) between the donor and the recipient 
defines a significant component of transplant al- 
lorejection. Although nonspecific pharmacologic 
immunosuppression f the host has facilitated cell 
migration, chimerism, and graft acceptance, these 
drugs have also caused significant morbidity includ- 
ing neoplasia and infection. 1-3 The endothelium of 
the transplant vasculature is the interface between 
an allograft and the host immune system. As such, it 
represents the target cell of early rejection. 4 Reduc- 
tion of the immunogenicity of endothelium by down- 
regulation of the expression of MHC class II genes is 
not yet possible. However, in this report, we have 
shown that random seeding of a rodent heart allograft 
with endothelium of recipient origin not only pheno- 
typically modifies the donor endothelium but facili- 
tates long-term survival. This simple technique, which 
has implications in both allotransplantation a d xeno- 
transplantation, results in a significant reduction in the 
requirement of immunosuppressive th rapy. 
Material and methods 
Preparation of endothelial cells. Rat endothelial cells 
were harvested from the epididymal rat pads of Lewis- 
RT11 (Lew) retired breeders (Harlan Sprague-Dawley, 
Indianapolis, Ind.) and placed in a 0.1% bovine serum 
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albumin solution. A 2 mg/m1 concentration fcollagenase 
A (Boehringer Mannheim, Indianapolis, Ind.) was used to 
digest he microvasculature of the tissue. The remaining 
cells underwent centrifugation through a Percoll gradient 
(Pharmacia, Uppsala, Sweden) at 30,000 rpm for 30 
minutes. A small proportion of cells were stained with 5 
/xl/106 cells of endothelial cell marker (Serotec, Oxford, 
England) to verify cell type. The endothelial cells were 
then cultured in a DMEM-10 medium (DMEM, 10% fetal 
bovine serum, L-glutamine 1.7 mmol/L [Gibco, Grand 
Island, N.Y.], crude endothelial growth factor 40 /xg/ml 
[Collaborative Biomedical Products, Bedford, Mass.], and 
heparin 5 U/ml, l x of 1 mol/L HEPES buffer solution 
[Gibco]). Cells were cultured at 37 ° C for 3 days in 75 ml 
Costar flasks (Cambridge, Mass.) before experimental use. 
Perfusion of endothelial cells into donor allografts. 
The heart of the Lewis-Brown Norway F 1 rat was har- 
vested and maintained on a modified Langendorff perfu- 
sion apparatus 5 in which the heart was ¢ontinually per- 
fused with a ¢al¢ium-free Krebs-Henseleit buffer, 95% 
oxygen, and 5% carbon dioxide at 4 ° C. The cultured 
endothelial ¢ells at a concentration of 3 × 106 in 5 ml of 
buffer were perfused randomly into the coronary ostia 
over 20 minutes. 
Heterotopic cardiac transplantation. Donor hearts 
were harvested from 250 to 300 gm male Lew × Brown 
Norway - RT1 n (BN) F1 hybrid rats. After cell perfusion 
they were heterotopically transplanted into 250 to 300 gm 
male Lew recipients by the te¢hnique of Ono and Lind- 
sey. 6 In brief, the graft was implanted to the abdominal 
great vessels. Is¢hemic time averaged 25 minutes. Each 
graft was evaluated by abdominal palpation. All animals 
received humane care in compliance with the "Principles 
of Laboratory Animal Care" formulated by the National 
Society for Medical Resear¢h and the "Guide for the Care 
and Use of Laboratory Animals" prepared by the Institute 
of Laboratory Animal Resour¢es and published by the 
National Institutes of Health (NIH Publication No. 86-23, 
revised 1985). 
Mixed lymphocyte cultures. Mixed lymphocyte cultures 
were performed in 96 well round-bottomed microtitre 
plates (Costar). Viable responding cells (4 × 105 cells per 
well) of mesenteric lymph node origin were cultured with 
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Figs. I and 2. Mixed lymphocyte cultures. The proliferative response of mesenteric lymph node cells (LN) 
harvested from untreated Lewis (RT1 l) (Lew) rats (Fig. 1) and transplanted Lew rats(Fig. 2). Stimulation 
is provided by x-irradiated (2000R) LN cells of Lew × Brown Norway (RT1 n) (BN) F1, Dark Agouti (DA) 
(RTlaVa), and Lew (RT11) rats. Cultures were set up in triplicate with a responder:stimulator ratio of 1:1 
(n = 3) over 9 days. The stimulation index on the ordinate axis reflects the cpm of the responders + 
stimulators/responders alone. The fange (error bars) was calculated for each day. P values were obtained 
by comparing [3H] thymidine uptake in cells from one day to the next. The Mann-Whitney U test was used 
for all of these comparisons. 
irradiated (2000 rad) viable lymph node stimulator cells 
(4 × 10 » cells per weil), in a total volume of 0.2 ml Excell 
5 solution (Excell 320, 20 ml supplement, 5% fetal calf 
serum, 2-mercaptoethanol 2.5 x 105 mol/L, penicillin 100 
U/tal, and streptomycin 100 mg/ml) in triplicate. The 
plates were incubated for 9 days at 37 ° C in 5% carbon 
dioxide and humidified air. For each assay six identical 
trays were set up so that cell proliferation could be 
assessed over a 9-day period. One tray was pulsed with 1 
BCi of [3H] thymidine per weil each day, beginning 4 days 
after the assays were set up. The time of the addition of 
[3H] thymidine is reported in Figs. 1 and 2. Cells were 
harvested onto filter paper using a PHD harvester (Cam- 
bridge Technology Inc., Watertown, Mass.) after a further 
culture of 6 hours. [3H] thymidine incorporation was 
evaluated in a Beckrnan liquid scintillation counter (Beck- 
man Instruments, Inc., Fullerton, Calif.) (2 minutes per 
sample, with a toluene-based seintillant). 
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Table I. Survival of Lew × BN F 1 (donor) cardiac allografis in treated and untreated Lew (recipient) rats 
Perfusion donor Endothelial cells Heart Heart Mean survival 
heart perfused donor recipient Immunotherapy n (days) 
No - BN × Lew F 1 Lew No 5 7 _+ 1 
No - BN × Lew F1 Lew Cyclosporine (1.5 mg/kg 5 7 -+ 1 
per day X 7 days) 
No BN × Lew F1 Lew Cyclosporine (15 mg/kg 5 >100 
per day x 7 days) 
Yes 3 x 106 BN × Lew F1 Lew No 5 12 + 2 
Yes 3 × 106 BN × Lew Fa Lew Cyclosporine (1.5 mg/kg 7 21 -- 3 
per day × 7 days) 
Yes 3 × 106 BN × Lew F 1 Lew Cyclosporine (1.5 mg/kg 7 30 -+ 3 
per day × 14 days) 
Yes 3 × 106 BN × Lew F 1 Lew Cyclosporine (1.5 mg/kg 7 >100 
per day x 50 days) 
Endothelial cells are of Lew origin. 
Endothelial cell labeling. Endothelial cells were 
treated with trypsin at 25 ° C. The cells were then centri- 
fuged (400 g) for 5 minutes. The resuspended cells were 
labeled with PKH-26 intercalating dye (Zynaxis Cell Sci- 
ence Inc., Malvern Pa.). This dye is excited at 550 nm and 
emits fluorescent (orange) light at 560 nm. 7 
Results 
In this strain combination (Lew × BN F 1 --> Lew) 
untreated Lew rats reject he allografts in 7 _+ 1 days 
(n = 5) (Table I). Allografts pretreated with endo- 
thelial cells survive for 12 _+ 2 days (p < 0.05) (n = 
5). Therapeutic cyclosporine (15 mg/kg per day for 7 
days) resulted in indefinite graft acceptance (n = 
5), 8 but subtherapeutic cyclosporine (1.5 mg/kg per 
day for 7 days) did not alter survival (7 +_ 1 days) 
(n = 5), nor did perfusion of the allografts with 
Krebs-Henseleit buffer alone. The combination of 
3 N 106 endothelial cells, of recipient origin, and 
subtherapeutic cyclosporine resulted in long-term 
survival of the heart transplants (>100 days) (n = 
7). 
So that we could determine whether these Lew 
long-term survivors were tolerant o the allograft 
antigens, they were transplanted ( ay 30) with split- 
thickness kin grafts of Lew x BN F] origin and 
simultaneous contralateral split-thickness skin grafts 
of a third-party (Dark Agouti-RT1 avl [DA]) origin. 
All split-thickness skin grafts were rejected at 15 _ 
3 days (n = 3). There was no significant difference in 
the fate of the DA split-thickness skin grafts when 
compared with the Lew × BN F 1 split-thickness skin 
grafts. Control experiments in Lew rats pretreated 
with subtherapeutic cyclosporine, but not a cardiac 
transplant, were performed and all split-thickness 
skin grafts were rejected at 17 _+ 2 days (n = 3) (p > 
0.05). The presence of the split-thickness skin grafts 
did not alter the fate of the heart grafts. In addition, 
mesenteric lymph node cells harvested from Lew 
long-term (50 days) survivors were cultured for 9 
days with irradiated lymph node cells of donor 
(Lew × BN F1) and third-party (DA) origin (n = 3) 
(see Figs. 1 and 2). 
The unidirectional mixed lymphocyte culture in 
Fig. 1 indicates day 8 as the point of maximum 
proliferation when responding cells were from un- 
treated Lew rats regardless of the source of irradi- 
ated stimulators. However, in Fig. 2, day 6 repre- 
sents the point of maximum proliferation in 
responding cells of transplanted Lew origin when 
stimulation was provided by irradiated (Lew × BN 
F1) cells. Furthermore, the stimulation index scale 
on the ordinate axis is rauch lower in Fig. 2 than in 
Fig. 1, indicating moderate nonspecific immunosup- 
pression in the transplanted host. Mitogenic stimu- 
lation of lymph hode cells from either control or 
experimental Lew rats, with 0.5/xg/ml Concanavalin 
A (Boehringer Mannhein GmbH, Mannheim, Ger- 
many) demonstrated a peak proliferative response 
after 36 hours or 72 hours of culture, respectively. 
There was no significant difference, however, in the 
stimulation index (p > 0.05) (data not shown). 
The rate of the perfused endothelial cells was 
determined by labeling the cells (n = 5) before 
injection, with PKH 26 dye, a fluorescent membrane 
linker. Because histologic frozen sections of heart 
allografts will spontaneously fluoresce light (green) 
in the 480 nm range (autofluorescence of macro- 
phages and vessel elastin), fluorescent light emission 
at a different region of the spectrum (550 nm) is 
required for successful trafficking studies (Figs. 3 
and 4). Fluorescent label is partitioned between 
daughter cells as a parent cell divides, justifying the 
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Figs. 3 and 4. Endothelial cell trafficking studies (n = 5). Labeled endothelial cells with PKH 26 
dye (orange) are seen to line intermyocardial capillaries 20 minutes after antegrade injection into the 
coronary arteries (Fig. 3). These frozen histologic sections were photographed with a fluorescent light at 
550 nm. Labeled daughter cells continue to fluoresce, with a weaker signal, in the same anatomic location 
15 days after transplantation (Fig. 4). Note the autofiuorescence of the elastin of a large blood vessel 
(green). 
smaller signal in Fig. 4 (15 days after transplanta- 
tion) when compared with Fig. 3 (20 minutes after 
injection). 
Discussion 
This simple reproducible te¢hnique not only fa- 
¢ilitates long-term survival in this rodent heterotopic 
cardiae allograft model but reduces the requirement 
for pharmacologic immunosuppression. We hypoth- 
esize that the seeding of donor organs with endo- 
thelial cells of recipient origin reduces immunoge- 
nicity by either masking the expression of the elass II 
MHC molecules or causing up-regulation or down- 
regulation of MHC or cell adhesion genes (or both) 
in the donor endothelium. 
It has previously been shown that the donor 
endothelial cell is immunogenic and its immuno- 
genic capacity is directly proportional to the extent 
of class II MHC antigen expression the cell 
surface. 9 The role of adhesion molecules in al- 
lorejection, however, is unclear. 
Normally, specialized microvascular endothelial 
cells promote leukocyte xtravasation i to lymphoid 
structures, a process that requires reciprocal recog- 
nition of leukocyte/endothelial ce l adhesion mole- 
culesJ ° In this way, endothelial cells can regulate 
the normal patterns of ystemic leukocyte migration. 
Endothelial cells also regulate inflammatory leuko- 
cyte infiltration, albeit by different sets of adhesion 
moleculesjl, 12 These leukocyte/endothelial adhe- 
sion systems are not allelic and can operate across 
allogeneic barriers. As a result, inflamed allograft 
endothelium can interact with host leukocytes to 
promote interstitial migration via mechanisms that 
are not associated with compromised vascular integ- 
rity. Consequently, the microvascular endothelium 
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of rejecting allografts is an active participant rather 
than a passive target of the rejection process. 
Leukocyte/endothelial adhesion systems associ- 
ated with inflammation and cell-mediated immunity 
that have been identified include LFA-1/ICAM- 
1,la, 13 CD2/LFA_3,12, 13 VLA_4/VCAM_l,13, 14 and 
CDw49e/fibronectin) 4 Antibodies to ICAM-1 and 
LFA-1 inteffere with cardiac allograft rejection in 
mice. 15 We are presently investigating the relative 
roles of MHC and cell adhesion molecules in our 
model. 
We do know that this phenomenon does not 
represent tolerance. First, the in vitro proliferation 
of lymphocytes harvested from transplanted rats, 
when stimulation was provided by donor-specific 
antigen, was not abrogated in comparison with 
control values. Second, split-thickness kin grafts of 
donor origin were rejected within control times. In 
the context of the mixed lymphocyte culture data, 
this latter observation with split-thickness kin grafts 
probably does not represent a case of tissue-specific 
antigenicity) 6 
The fact that these endothelial cells persist and 
proliferate in the allograft vascular tree suggests that 
the immunomodulation s a dynamic process. We are 
presenüy investigating techniques to transfect hese 
endothelial cells with a "tag" such that trafficking 
studies may be performed beyond 15 days. 
The results have obvious clinical applications. For 
instance, all prospective recipients of vascularized 
allografts (i.e., heart, liver, kidney, lung, and pan- 
creas) could have autologous endothelial cells in 
culture. Just before transplantation the cadaveric 
donor allograft, washed with University of Wiscon- 
sin preservation solution, would be perfused with 
these cultured cells. These efforts may reduce the 
requirement of host immunosuppression and its asso- 
ciated complications. Furthermore, this system could 
easily be applied to a model of xenotransplantation. 
We thank S. K. Williams, PhD, and J. B. Moying, MS, 
University of Arizona, for their assistance inthe technique 
of preparation of microvessel ndothelium. 
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